Panretinal Photocoagulation Versus Ranibizumab for Proliferative Diabetic Retinopathy: Should Baseline Characteristics Affect Choice of Treatment?

Related

• 

  Prophylactic Ranibizumab for Exudative AMD in Vulnerable Eyes With Nonexudative AMD Trial (PREVENT) A Prospective Controlled Clinical Trial

  Maziar Lalezary, MD

  Annual Meeting Talks

  2018

• 

  Complications or Are They: Why We Can NEVER Get Enough ReST

  Jeffrey S. Heier, MD

  Peter K. Kaiser, MD FASRS

  Geoffrey G. Emerson, MD, PhD, FASRS

  J. Michael Jumper, MD, FASRS

  Ehab N. ELRAYES, MD, PhD ,FASRS

  Daniel Simhaee, MD

  ASSAF DOTAN, MD

  Paul Hahn, MD, PhD, FASRS

  Philip J. Ferrone, MD, FASRS

  Annual Meeting Talks

  2018

• 

  Factors Predicting Vitreous Hemorrhage or Neovascularization after Pan-Retinal Photocoagulation in Proliferative Diabetic Retinopathy

  Jose Davila, MD

  Updates from the Field

  2020